Love Pharma (CSE:LUV) Inc has announced the debut of its first two products - Bloom and Auralief.
The Vancouver, British Columbia-based company said that Bloom is a topical female arousal gel, while Auralief is an oral muco-adhesive sublingual strips, infused with THC and CBD.
“It is with great excitement that we are able to announce the launch of our first two fully-branded products, Bloom and Auralief. We believe these two products within our strong portfolio of intellectual property can quickly command significant market share in the shortest period,” said Zachary Stadnyk, CEO of Love Pharma.
He added: “We look forward to updating our investors as we progress through the rollout of these first two products and subsequently, the company’s therapeutic and wellness products in a strategic, staggered approach.”
READ: Love Pharma announces development of muco-adhesive strip technology for delivery of psilocybin
The company said that Bloom addresses the issue of female sexual dysfunction, and can be sold as an over-the-counter product without CBD or THC.
"Bringing any product to market is exciting, and with Bloom — our exclusive formula is proven to enhance women’s arousal and we’re excited about our new branded launch," said Joshua Maurice, COO of Love Pharma.
Auralief, meanwhile, would enhance the bioavailability of THC and CBD, thereby increasing the impact of its health elements. Maurice said that when it comes to product development in the wellness and psychedelics markets, “discretion and convenience are the names of the game; and Auralief provides both.”
“With its ease-of-use and enhanced THC/CBD delivery system, we believe this multi-patented sublingual strip will be one of our most prominent consumer products,” Maurice added.
Love Pharma also announced that it has entered into contractual agreements for marketing, communication, shareholder engagement, and social media communications. The marketing and communication program will include certain investor relations activities and is designed to provide improved visibility in the company’s current and planned operations.
In addition, Love Pharma has entered into a contract with Atkien Check to list the company on the Frankfurt Stock Exchange and provide investor awareness as needed. The company has also engaged Independent Financial for an aggregate amount to date of US$115,466.
With a focus on the global sexual health and wellness markets, Love Pharma is focused to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
Contact Ritika at ritika@proactiveinvestors.com